Keryx Biopharmaceuticals Announces That Congress Delays Implementation Of Oral-Only ESRD-Related Drugs, Including Phosphate Binders, In The Bundled ESRD Prospective Payment System By Two-Years, Until January 2016

Cautionary Statement

Some of the statements included in this press release, particularly those relating to the potential effect on the market opportunity for Zerenex (ferric citrate) due to the two-year delay in the inclusion of the oral-only ESRD-related drugs in the bundled reimbursement system, and those anticipating any clinical trials and business prospects for Zerenex, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); the risk that the data (both safety and efficacy) from the long-term Phase 3 trial of Zerenex (ferric citrate) will not coincide with the data analyses from previous clinical trials reported by the Company; the risk that the data (both safety and efficacy) from the ongoing Phase 2 study in non-dialysis dependent chronic kidney disease will be negative or inconclusive; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at  http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT: Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: [phone]E-mail: [e-mail] 

SOURCE Keryx Biopharmaceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

« First ‹ Previous 1 2